BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 8938531)

  • 1. HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily (southern Italy).
    Magrin S; Craxi A; Fabiano C; Marino L; Fiorentino G; Lo Iacono O; Volpes R; Di Marco V; Almasio P; Vaccaro A; Urdea MS; Wilber JC; Bonura C; Gianguzza F; Capursi V; Filiberti S; Stuyver L; Pagliaro L
    J Hepatol; 1996 Nov; 25(5):583-90. PubMed ID: 8938531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotype, serum level of hepatitis C virus RNA and liver histology as predictors of response to interferon-alpha 2a therapy in Japanese patients with chronic hepatitis C.
    Mizokami M; Orito E; Gibo Y; Suzuki K; Ohba K; Ohno T; Lau JY
    Liver; 1996 Feb; 16(1):23-7. PubMed ID: 8868074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum.
    Ampurdanés S; Olmedo E; Maluenda MD; Forns X; López-Labrador FX; Costa J; Sánchez-Tapias JM; de Anta MT; Rodés J
    J Hepatol; 1996 Dec; 25(6):827-32. PubMed ID: 9007709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotype, viral load and age as independent predictors of treatment outcome of interferon-alpha 2a treatment in patients with chronic hepatitis C. Construct group.
    Bell H; Hellum K; Harthug S; Maeland A; Ritland S; Myrvang B; von der Lippe B; Raknerud N; Skaug K; Gutigard BG; Skjaerven R; Prescott LE; Simmonds P
    Scand J Infect Dis; 1997; 29(1):17-22. PubMed ID: 9112292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum hepatitis C virus RNA level as a predictor of subsequent response to interferon-alpha therapy in Japanese patients with chronic hepatitis C.
    Orito E; Mizokami M; Nakano T; Terashima H; Nojiri O; Sakakibara K; Mizuno M; Ogino M; Nakamura M; Matsumoto Y
    J Med Virol; 1994 Dec; 44(4):410-4. PubMed ID: 7897373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response.
    Kasahara A; Hayashi N; Mochizuki K; Oshita M; Katayama K; Kato M; Masuzawa M; Yoshihara H; Naito M; Miyamoto T; Inoue A; Asai A; Hijioka T; Fusamoto H; Kamada T
    J Hepatol; 1997 Mar; 26(3):574-83. PubMed ID: 9075665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group.
    Nousbaum JB; Pol S; Nalpas B; Landais P; Berthelot P; Bréchot C
    Ann Intern Med; 1995 Feb; 122(3):161-8. PubMed ID: 7810932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of viral genotype and level of viremia on the severity of liver injury and the response to interferon therapy in Spanish patients with chronic C infection.
    Fernández I; Castellano G; Domingo MJ; Fuertes A; Colina F; Canga F; de la Cruz FJ; de la Cámara AG; Solís JA
    Scand J Gastroenterol; 1997 Jan; 32(1):70-6. PubMed ID: 9018770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HCV-RNA levels play an important role independently of genotype in predicting response to interferon therapy.
    Picciotto A; Campo N; Brizzolara R; Sinelli N; Poggi G; Grasso S; Celle G
    Eur J Gastroenterol Hepatol; 1997 Jan; 9(1):67-9. PubMed ID: 9031902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus (HCV) RNA level determined by second-generation branched-DNA probe assay as predictor of response to interferon treatment in patients with chronic HCV viremia.
    Furusyo N; Hayashi J; Kashiwagi K; Nakashima H; Nabeshima S; Sawayama Y; Kinukawa N; Kashiwagi S
    Dig Dis Sci; 2002 Mar; 47(3):535-42. PubMed ID: 11911338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon alpha 2a therapy.
    Suzuki T; Tanaka E; Matsumoto A; Urushihara A; Sodeyama T
    J Med Virol; 1995 Jun; 46(2):162-8. PubMed ID: 7636506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.
    Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M
    J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parameters predicting response to alpha-interferon treatment in chronic hepatitis C.
    Glück T; Seelig R; Dette S; Bühring HJ; Renz M; Kwon S; Wiedmann KH; Weber P
    Hepatogastroenterology; 1997; 44(14):484-91. PubMed ID: 9164523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-alpha treatment of hepatitis C virus-associated mixed cryoglobulinemia.
    Polzien F; Schott P; Mihm S; Ramadori G; Hartmann H
    J Hepatol; 1997 Jul; 27(1):63-71. PubMed ID: 9252075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical value of grading and staging scores for predicting a long-term response and evaluating the efficacy of interferon therapy in chronic hepatitis C.
    Shindo M; Arai K; Okuno T
    J Hepatol; 1997 Mar; 26(3):492-7. PubMed ID: 9075654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of hepatitis C viremia in patients receiving hemodialysis.
    Umlauft F; Gruenewald K; Weiss G; Kessler H; Urbanek M; Haun M; Santner B; Koenig P; Keeffe EB
    Am J Gastroenterol; 1997 Jan; 92(1):73-8. PubMed ID: 8995941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group.
    Chemello L; Cavalletto L; Casarin C; Bonetti P; Bernardinello E; Pontisso P; Donada C; Belussi F; Martinelli S; Alberti A
    Ann Intern Med; 1996 Jun; 124(12):1058-60. PubMed ID: 8633819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients.
    Brouwer JT; Nevens F; Kleter B; Elewaut A; Adler M; Brenard R; Chamuleau RA; Michielsen PP; Pirotte J; Hautekeete ML; Weber J; Bourgeois N; Hansen BE; Bronkhorst CM; ten Kate FJ; Heijtink RA; Fevery J; Schalm SW
    J Hepatol; 1998 Jun; 28(6):951-9. PubMed ID: 9672169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleotide sequence variations in the internal ribosome entry site of hepatitis C virus-1b: no association with efficacy of interferon therapy or serum HCV-RNA levels.
    Yamamoto C; Enomoto N; Kurosaki M; Yu SH; Tazawa J; Izumi N; Marumo F; Sato C
    Hepatology; 1997 Dec; 26(6):1616-20. PubMed ID: 9398006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon treatment for chronic hepatitis C infection in hemophiliacs--influence of virus load, genotype, and liver pathology on response.
    Hanley JP; Jarvis LM; Andrew J; Dennis R; Hayes PC; Piris J; Lee R; Simmonds P; Ludlam CA
    Blood; 1996 Mar; 87(5):1704-9. PubMed ID: 8634415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.